Idemia working on digital health passport for borders with Kiwi immunity-detection company
Idemia has partnered with Orbis Diagnostics, an immunity-detection technology provider based in New Zealand, to support research and development into quantitative immunity testing combined with its digital ID technology at its Canberra Innovation Lab.
Orbis Diagnostics brings its platform, while Idemia brings its border risk management, passenger flow facilitation and digital identity expertise. Passenger flow facilitation is enabled by touchless biometrics like facial recognition.
The immunity screening platform will likely be introduced at airports in Australia and New Zealand as early as mid-2021, according to the announcement, before rolling out across the Asia-Pacific region.
Australia launched a system for border checks with technology from Idemia and Unisys last year.
“This platform has been designed specifically for high-volume and non-laboratory environments, such as airports,” says Orbis Diagnostics CEO Brent Ogilvie. “The process is fast, and once a person’s immunity has been accurately determined, they could bypass quarantine with the assurance there is no substantial risk of causing a fresh outbreak.”
“Now that the world is deploying the first-generation of COVID-19 vaccines, we expect immunity screening to become a crucial element of the complete solution supporting the safe resumption of international travel,” comments Idemia Managing Director of Oceania Xavier Assouad.
Assouad says Idemia plans to integrate its mobile ID and border control platform to perform risk assessments.
“This would reduce the probability of fraudulent immunity certification and enable trusted results to be shared with border agencies using the ICAO-defined Digital Sealing IDEMIA provides,” he explains. “IDEMIA aims to provide a global response and explore the integration with IDEMIA’s passenger flow facilitation platform, in order to provide a seamless, end to end solution covering all steps of the journey at both departure and arrival.”